Mario Gabelli Cerevel Therapeutics Holdings, Inc. Transaction History

Gamco Investors, Inc. Et Al

  • $9 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
SELL
$38.96 - $42.75 $369,613 - $405,569
-9,487 Reduced 13.78%
59,350 $2.43 Million
Q1 2024

May 14, 2024
BUY
$40.88 - $43.27 $2.81 Million - $2.98 Million
68,837 New
68,837 $2.91 Million

Others Institutions Holding CERE

# of Institutions
9
Shares Held
5.01M
Call Options Held
3.3K
Put Options Held
0
View Full List

About Cerevel Therapeutics Holdings, Inc.

CERE Quotes by TradingView
  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track Mario Gabelli's Portfolio

Track Mario Gabelli Portfolio

Follow Mario Gabelli (Gamco Investors, Inc. Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gamco Investors, Inc. Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Gamco Investors, Inc. Et Al and Mario Gabelli with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email